FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1500668920> ?p ?o ?g. }

• W1500668920 abstract "In over 20 states, cancer patients have access to cannabinoids (aka medical marijuana) to treat symptoms of chemotherapy, such as nausea and lack of appetite. However, new evidence, both scientific and empirical, suggests that higher doses of cannabinoids may be an effective adjuvant alongside traditional chemotherapy agents, such as Gemcitibine. While daily dosages of 10 to 40mg are commonly used to control nausea, pancreatic cancer cells are known to over express the endo-cannabinoid receptor CB1 one hundred fold, requiring much higher dosages. Cannabinoids target different receptors than traditional chemotherapy agents with low combinatorial toxicity, and as such present a class of new treatments. In an n=1 study of a patient with stage IV pancreatic adeno-carcinoma, we augmented the standard Gemcitibine chemotherapy with balanced initial doses of 50mg THC and 50mg CBD that increased over a four week period to achieve a 12.5 mg/kg total cannabinoid dosage. Curiously, after ten days the patient stopped presenting signs of cannabinoid use, such as red eyes, slurred speech and clumsiness. However, the patient’s CA-19-9 marker increased from 8,800 ul/L at diagnosis to 25,500. Over the next four weeks, dosage of CBD was held constant and THC was increased to 1050mg daily for a combined dosage of 20mg/kg. At week 6, the CA-19-9 marker began decreasing and cannabinoid dosage was leveled off, although a higher dosage was planned for weeks 8-12. At week 15, CA-19-9 markers dropped to pre-diagnosis levels and a CAT scanned revealed shrinkage of the tumor. Rate of decrease in CA-19-9 exceeded previously published rates for patients with positive outcomes from Gemcitibine alone. Although many pancreatic cancer patients have access to cannabinoids, issues such as potency, purity and bio-availablity will impact future adjuvant cannabinoid therapies. We have addressed these issues with existing technology in the hopes of supporting large scale trials that will examine the efficacy of Gemcitibine + cannabinoid adjuvants in the treatment of pancreatic cancer. Citation Format: Andy D. Hospodor. Cannabinoids as an adjuvant therapy for pancreatic cancer. [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Innovations in Research and Treatment; May 18-21, 2014; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2015;75(13 Suppl):Abstract nr B83." @default.
• W1500668920 created "2016-06-24" @default.
• W1500668920 creator A5008933950 @default.
• W1500668920 date "2015-06-30" @default.
• W1500668920 modified "2023-10-14" @default.
• W1500668920 title "Abstract B83: Cannabinoids as an adjuvant therapy for pancreatic cancer" @default.
• W1500668920 doi "https://doi.org/10.1158/1538-7445.panca2014-b83" @default.
• W1500668920 hasPublicationYear "2015" @default.
• W1500668920 type Work @default.
• W1500668920 sameAs 1500668920 @default.
• W1500668920 citedByCount "0" @default.
• W1500668920 crossrefType "proceedings-article" @default.
• W1500668920 hasAuthorship W1500668920A5008933950 @default.
• W1500668920 hasConcept C121608353 @default.
• W1500668920 hasConcept C126322002 @default.
• W1500668920 hasConcept C148001335 @default.
• W1500668920 hasConcept C162156334 @default.
• W1500668920 hasConcept C170493617 @default.
• W1500668920 hasConcept C2776694085 @default.
• W1500668920 hasConcept C2778938600 @default.
• W1500668920 hasConcept C2780210213 @default.
• W1500668920 hasConcept C2780580376 @default.
• W1500668920 hasConcept C2780871563 @default.
• W1500668920 hasConcept C71924100 @default.
• W1500668920 hasConcept C90924648 @default.
• W1500668920 hasConcept C98274493 @default.
• W1500668920 hasConceptScore W1500668920C121608353 @default.
• W1500668920 hasConceptScore W1500668920C126322002 @default.
• W1500668920 hasConceptScore W1500668920C148001335 @default.
• W1500668920 hasConceptScore W1500668920C162156334 @default.
• W1500668920 hasConceptScore W1500668920C170493617 @default.
• W1500668920 hasConceptScore W1500668920C2776694085 @default.
• W1500668920 hasConceptScore W1500668920C2778938600 @default.
• W1500668920 hasConceptScore W1500668920C2780210213 @default.
• W1500668920 hasConceptScore W1500668920C2780580376 @default.
• W1500668920 hasConceptScore W1500668920C2780871563 @default.
• W1500668920 hasConceptScore W1500668920C71924100 @default.
• W1500668920 hasConceptScore W1500668920C90924648 @default.
• W1500668920 hasConceptScore W1500668920C98274493 @default.
• W1500668920 hasLocation W15006689201 @default.
• W1500668920 hasOpenAccess W1500668920 @default.
• W1500668920 hasPrimaryLocation W15006689201 @default.
• W1500668920 hasRelatedWork W1495861453 @default.
• W1500668920 hasRelatedWork W1544543731 @default.
• W1500668920 hasRelatedWork W1917087166 @default.
• W1500668920 hasRelatedWork W1979760469 @default.
• W1500668920 hasRelatedWork W1992445810 @default.
• W1500668920 hasRelatedWork W2029309368 @default.
• W1500668920 hasRelatedWork W2045010880 @default.
• W1500668920 hasRelatedWork W2045951807 @default.
• W1500668920 hasRelatedWork W2048535059 @default.
• W1500668920 hasRelatedWork W2057763026 @default.
• W1500668920 hasRelatedWork W2059310179 @default.
• W1500668920 hasRelatedWork W2080473857 @default.
• W1500668920 hasRelatedWork W2094771676 @default.
• W1500668920 hasRelatedWork W2142468847 @default.
• W1500668920 hasRelatedWork W2413610531 @default.
• W1500668920 hasRelatedWork W2414953977 @default.
• W1500668920 hasRelatedWork W2809263631 @default.
• W1500668920 hasRelatedWork W3205206586 @default.
• W1500668920 hasRelatedWork W322264292 @default.
• W1500668920 hasRelatedWork W97476306 @default.
• W1500668920 isParatext "false" @default.
• W1500668920 isRetracted "false" @default.
• W1500668920 magId "1500668920" @default.
• W1500668920 workType "article" @default.